Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025814902> ?p ?o ?g. }
- W3025814902 endingPage "100529" @default.
- W3025814902 startingPage "100529" @default.
- W3025814902 abstract "Atherosclerosis is a chronic inflammatory disease responsible for most cases of heart disease and stroke in Western countries. The cytotoxic drug cyclophosphamide (CPA) can modulate immune functions, and it has therefore been used to treat patients with autoimmune diseases. Extension of survival of patients with severe atherosclerosis has been reported after CPA treatment, but the underlying mechanism is still poorly understood.We have investigated the effects of CPA in a murine model of atherosclerosis. Continuous oral administration of low-dose CPA (20 mg/kg/day) prevented atherosclerosis in apolipoprotein E-deficient (apoE-/-) mice fed with a high fat diet. After 12 weeks, CPA treatment delayed progression of atherosclerosis in the mice (9.92% vs 3.32%, P < 0.05, n = 7) and reduced the macrophage content of plaques (1.228 vs 0.2975 mm2, P < 0.001). Flow cytometry (FACS) showed that, in peripheral blood and spleen cells, the numbers of B cells and inflammatory T cells (Th1 cells) decreased, and inflammatory monocytes also decreased. However, there were no differences in the bone marrow cells between the two groups. The mRNA levels in the aorta showed significantly decreased inflammatory cytokine (interleukin-6) (P < 0.05), and tended to increase anti-inflammatory cytokine (argininase-1), but no significant differences between the two groups. High dose CPA has cardiotoxicity, but the dose used in this study did not show significant cardiotoxicity.The results demonstrate that oral treatment with CPA inhibits initiation and progression of atherosclerosis in the apoE-/- mouse model through immunomodulatory effects on lymphoid and inflammatory cells." @default.
- W3025814902 created "2020-05-21" @default.
- W3025814902 creator A5008559119 @default.
- W3025814902 creator A5012506740 @default.
- W3025814902 creator A5020285512 @default.
- W3025814902 creator A5029275273 @default.
- W3025814902 creator A5053003991 @default.
- W3025814902 creator A5063613258 @default.
- W3025814902 creator A5073757155 @default.
- W3025814902 creator A5076375061 @default.
- W3025814902 creator A5090140666 @default.
- W3025814902 date "2020-06-01" @default.
- W3025814902 modified "2023-10-16" @default.
- W3025814902 title "Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis" @default.
- W3025814902 cites W1525684755 @default.
- W3025814902 cites W1633176708 @default.
- W3025814902 cites W1929987490 @default.
- W3025814902 cites W1934974002 @default.
- W3025814902 cites W1965284496 @default.
- W3025814902 cites W1965579398 @default.
- W3025814902 cites W1967376766 @default.
- W3025814902 cites W1968350849 @default.
- W3025814902 cites W1969445722 @default.
- W3025814902 cites W1970295969 @default.
- W3025814902 cites W1973834397 @default.
- W3025814902 cites W1990478798 @default.
- W3025814902 cites W1996020742 @default.
- W3025814902 cites W1999742425 @default.
- W3025814902 cites W1999819607 @default.
- W3025814902 cites W2003768389 @default.
- W3025814902 cites W2011375891 @default.
- W3025814902 cites W2015141049 @default.
- W3025814902 cites W2015700821 @default.
- W3025814902 cites W2020245957 @default.
- W3025814902 cites W2022254967 @default.
- W3025814902 cites W2024278752 @default.
- W3025814902 cites W2046099126 @default.
- W3025814902 cites W2048488403 @default.
- W3025814902 cites W2054472394 @default.
- W3025814902 cites W2056993290 @default.
- W3025814902 cites W2062685715 @default.
- W3025814902 cites W2066963386 @default.
- W3025814902 cites W2070671835 @default.
- W3025814902 cites W2075796333 @default.
- W3025814902 cites W2079242778 @default.
- W3025814902 cites W2080028713 @default.
- W3025814902 cites W2083200530 @default.
- W3025814902 cites W2093705034 @default.
- W3025814902 cites W2098537370 @default.
- W3025814902 cites W2100595735 @default.
- W3025814902 cites W2100809362 @default.
- W3025814902 cites W2111609803 @default.
- W3025814902 cites W2116582392 @default.
- W3025814902 cites W2122537827 @default.
- W3025814902 cites W2131969939 @default.
- W3025814902 cites W2136071171 @default.
- W3025814902 cites W2142462591 @default.
- W3025814902 cites W2147181044 @default.
- W3025814902 cites W2156013098 @default.
- W3025814902 cites W2158380859 @default.
- W3025814902 cites W2158525135 @default.
- W3025814902 cites W2162641568 @default.
- W3025814902 cites W2166118660 @default.
- W3025814902 cites W2168660808 @default.
- W3025814902 cites W2197167222 @default.
- W3025814902 cites W2299083791 @default.
- W3025814902 cites W2801966321 @default.
- W3025814902 cites W2904892687 @default.
- W3025814902 cites W2946688474 @default.
- W3025814902 cites W4233144883 @default.
- W3025814902 cites W4237932865 @default.
- W3025814902 cites W4380199576 @default.
- W3025814902 cites W80392228 @default.
- W3025814902 doi "https://doi.org/10.1016/j.ijcha.2020.100529" @default.
- W3025814902 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7300380" @default.
- W3025814902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32577494" @default.
- W3025814902 hasPublicationYear "2020" @default.
- W3025814902 type Work @default.
- W3025814902 sameAs 3025814902 @default.
- W3025814902 citedByCount "6" @default.
- W3025814902 countsByYear W30258149022020 @default.
- W3025814902 countsByYear W30258149022021 @default.
- W3025814902 countsByYear W30258149022022 @default.
- W3025814902 countsByYear W30258149022023 @default.
- W3025814902 crossrefType "journal-article" @default.
- W3025814902 hasAuthorship W3025814902A5008559119 @default.
- W3025814902 hasAuthorship W3025814902A5012506740 @default.
- W3025814902 hasAuthorship W3025814902A5020285512 @default.
- W3025814902 hasAuthorship W3025814902A5029275273 @default.
- W3025814902 hasAuthorship W3025814902A5053003991 @default.
- W3025814902 hasAuthorship W3025814902A5063613258 @default.
- W3025814902 hasAuthorship W3025814902A5073757155 @default.
- W3025814902 hasAuthorship W3025814902A5076375061 @default.
- W3025814902 hasAuthorship W3025814902A5090140666 @default.
- W3025814902 hasBestOaLocation W30258149021 @default.
- W3025814902 hasConcept C126322002 @default.
- W3025814902 hasConcept C134018914 @default.
- W3025814902 hasConcept C154317977 @default.